Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.
Melanocortin receptors are linked to several inflammatory diseases, and genetic variations may influence these associations, but specific evidence and clinical significance are not detailed in this review.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This review discusses the polymorphisms of melanocortin receptor genes and their associations with various inflammatory traits and diseases. It highlights the involvement of these receptors in conditions such as melanoma, obesity, and major depressive disorder. The review also mentions FDA-approved melanocortin agonists, including Bremelanotide, without making therapeutic claims.
Abstract
Melanocortin receptors (MCRs) are responsible for various functions ranging from skin pigmentation, regulation of appetite, stress response and cognition, steroid synthesis, and energy balance to cellular regeneration and immunomodulation. The genetic polymorphism with tissue distribution ranging from the brain, limbic system, and adrenal cortex to neutrophils, monocytes, and macrophages is evident in MCRs. The mutations in MC1R, MC2R, MC3R, and MC4R genes are associated with risk of melanoma, familial glucocorticoid deficiency, obesity, and type 2 diabetes mellitus, respectively. Meanwhile, MC1R, MC2R, and MC5R genes are involved in the risk of major depressive disorder. Melanocortin receptors are involved in different inflammatory disorders, i.e., atopic dermatitis, autoimmune uveitis, sarcoidosis, respiratory diseases, multiple sclerosis, scleroderma, inflammatory bowel disease, amyotrophic lateral sclerosis, Alzheimer's disease, arthritis, and reperfusion injury. Several newer therapeutic agents related to MCRs have numerous advantages over the current anti-inflammatory drugs, demonstrating therapeutic relevance. Among them, α-MSH analogs play a role in atopic dermatitis and scleroderma, and MC1R agonist Dersimelagon has shown effectiveness in systemic sclerosis. The FDA has recently approved the repository corticotropin injection (RCI) to treat sarcoidosis. The FDA has also approved various melanocortin agonists, i.e., Bremelanotide, Afamelanotide, and Setmelanotide, for the treatment of hypoactive sexual desire disorder, Erythropoietic protoporphyria, and obesity, due to pro-opiomelanocortin and leptin receptor deficiency, respectively. Therefore, this review aims to summarize the function and genetic polymorphism of melanocortin receptors, regulatory pathways involving MCRs, and the existing evidence of the prime effect of MCRs on inflammatory responses via different mechanisms and their potential therapeutic use in inflammatory diseases.
Background
The paper addresses the role of melanocortin receptors in inflammation and their potential genetic polymorphisms. Prior research has indicated that these receptors may influence inflammatory responses, but the specific genetic variations and their implications remain unclear. This study aims to clarify the association between these polymorphisms and inflammatory diseases.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.